Abstract:Objective To explore the efficacy of second-line treatment chemotherapy regimens TCF (Docetaxel combined with fluorouracil and cisplatin) and FOLFIRI (rinotecan combined with fluorouracil and calcium leucovorin) after failure of chemotherapy of fluorouracil combined with oxaliplatin for the treatment of advanced gastric cancer. Methods A total of 62 hospitalized patients from January 2013 to December 2014 who were definitely diagnosed as gastric cancer by pathologically and were progression after first-line chemotherapy (FOLFOX, SOX, XELOX) were selected. The patients were divided into TCF group (n=32) and FOLFIRI group (n=30) by randomized allocation. Efficacy and adverse reactions in two groups were observed. Results There were no significant differences in clinical effective rate and control rate between TCF group and FOLFIRI group (12.5% vs 10.0%; 59.3% vs 60.0%; all P>0.05). There were no significant differences in median progression free time (PFS) and median overall survival (OS) between TCF group and FOLFIRI group (3.2 months vs 3.1 months; 5.8 months vs 5.3 months; all P>0.05) . There were no significant differences in leukopenia, thrombocytopenia, hemoglobin decrease, nausea, vomiting, fatigue and liver function damage between two groups (all P>0.05). The incidences of diarrhea and cholinergic syndrome in TCF group were significantly lower than those in FOLFIRI group (all P<0.05), and the incidence of oral mucositis in TCF group were significantly higher than that in FOLFIRI group (P<0.05). Conclusion After failure of chemotherapy of fluorouracil combined with oxaliplatin, the efficacy of TCF and FOLFIRI second-line chemotherapy regimens is similar, but their adverse reactions were different.